LUCIA
GONZALEZ CORTIJO
PROFESOR
Instituto de Salud Carlos III
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (2)
2020
-
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
Breast Cancer Research, Vol. 22, Núm. 1
-
Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)
European Journal of Cancer Care, Vol. 29, Núm. 4